NASDAQ:BLFS BioLife Solutions - BLFS Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioLife Solutions, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $20.78 -0.06 (-0.29%) (As of 03/30/2023 12:00 AM ET) Add Compare Share Share Today's Range$20.55▼$21.3150-Day Range$19.50▼$26.0752-Week Range$10.40▼$26.96Volume225,371 shsAverage Volume326,019 shsMarket Capitalization$888.76 millionP/E RatioN/ADividend YieldN/APrice Target$30.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media BioLife Solutions MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside44.4% Upside$30.00 Price TargetShort InterestBearish5.38% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.24Based on 5 Articles This WeekInsider TradingSelling Shares$1.73 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.41) to $0.23 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.96 out of 5 starsMedical Sector588th out of 1,009 stocksElectromedical Equipment Industry11th out of 23 stocks 3.5 Analyst's Opinion Consensus RatingBioLife Solutions has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $30.00, BioLife Solutions has a forecasted upside of 44.4% from its current price of $20.78.Amount of Analyst CoverageBioLife Solutions has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.38% of the float of BioLife Solutions has been sold short.Short Interest Ratio / Days to CoverBioLife Solutions has a short interest ratio ("days to cover") of 6.7.Change versus previous monthShort interest in BioLife Solutions has recently increased by 10.42%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldBioLife Solutions does not currently pay a dividend.Dividend GrowthBioLife Solutions does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BLFS. Previous Next 2.4 News and Social Media Coverage News SentimentBioLife Solutions has a news sentiment score of 0.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for BioLife Solutions this week, compared to 1 article on an average week.Search InterestOnly 3 people have searched for BLFS on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.MarketBeat Follows3 people have added BioLife Solutions to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BioLife Solutions insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,731,510.00 in company stock.Percentage Held by InsidersOnly 3.30% of the stock of BioLife Solutions is held by insiders.Percentage Held by Institutions89.82% of the stock of BioLife Solutions is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for BioLife Solutions are expected to grow in the coming year, from ($0.41) to $0.23 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioLife Solutions is -6.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BioLife Solutions is -6.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBioLife Solutions has a P/B Ratio of 2.44. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About BioLife Solutions (NASDAQ:BLFS) StockBioLife Solutions, Inc. engages in the development, manufacture and marketing of bio preservation tools for cells and tissues. Its product offerings include proprietary hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs, generic blood stem cell freezing and cell thawing media products and custom product formulation and custom packaging services. The company was founded by Boris Rubinsky in 1987 and is headquartered in Bothell, WA.Read More Receive BLFS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioLife Solutions and its competitors with MarketBeat's FREE daily newsletter. Email Address BLFS Stock News HeadlinesMarch 25, 2023 | americanbankingnews.comAby J. Mathew Sells 10,000 Shares of BioLife Solutions, Inc. (NASDAQ:BLFS) StockMarch 24, 2023 | markets.businessinsider.comLake Street Reaffirms Their Buy Rating on BioLife Solutions (BLFS)March 31, 2023 | The Oxford Club (Ad)JP Morgan analyst: Oil to hit $380 per barrelJP Morgan analysts have pegged the future price of oil at $380 per barrel. That would send oil companies skyrocketing. But there is one investment set to outperform all the rest.March 23, 2023 | markets.businessinsider.comMaxim Group Keeps Their Buy Rating on BioLife Solutions (BLFS)March 17, 2023 | finance.yahoo.comQ4 2022 BioLife Solutions Inc Earnings CallMarch 17, 2023 | finanznachrichten.deBioLife Solutions, Inc.: BioLife Solutions Reports Preliminary and Unaudited 2022 Fourth Quarter and Full Year Financial ResultsMarch 16, 2023 | seekingalpha.comBioLife Solutions GAAP EPS of -$1.15 misses by $0.99, revenue of $44.26M beats by $0.94MMarch 16, 2023 | finance.yahoo.comBioLife Solutions Reports Preliminary and Unaudited 2022 Fourth Quarter and Full Year Financial ResultsMarch 31, 2023 | The Oxford Club (Ad)JP Morgan analyst: Oil to hit $380 per barrelJP Morgan analysts have pegged the future price of oil at $380 per barrel. That would send oil companies skyrocketing. But there is one investment set to outperform all the rest.March 15, 2023 | msn.comBioLife Solutions's Earnings OutlookMarch 10, 2023 | msn.comUnitedHealth (UNH) Plan in Indiana to Offer Pathways ProgramMarch 10, 2023 | finance.yahoo.comBioLife Solutions Reports Immaterial Financial Exposure to Silicon Valley BankMarch 9, 2023 | finance.yahoo.comBioLife Solutions to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 16, 2023March 1, 2023 | finance.yahoo.comBioLife Solutions Launches Ultraguard™ -70°C Phase Change Material (PCM) Accessory to Provide Backup Cooling in ULT Freezers and Dry Ice Alternative for Benchtop Biologic Material StorageFebruary 17, 2023 | seekingalpha.comBLFS BioLife Solutions, Inc.January 17, 2023 | finance.yahoo.comBioLife Solutions Announces 2023 Analyst Day & Participation in Upcoming Investor ConferencesJanuary 10, 2023 | finance.yahoo.comBioLife Solutions Named One of Seattle Business Magazine's Washington's Best Companies to Work ForJanuary 9, 2023 | finance.yahoo.comBioLife Solutions Announces 2022 Fourth Quarter and Full Year Preliminary Unaudited Revenue and Introduces 2023 Revenue GuidanceJanuary 7, 2023 | seekingalpha.comBioLife Solutions: Inventory Movement A Key Benchmarking Factor, Retain HoldJanuary 6, 2023 | finance.yahoo.comIs BioLife Solutions, Inc. (NASDAQ:BLFS) Potentially Undervalued?January 5, 2023 | forbes.comBioLife SolutionsDecember 19, 2022 | finance.yahoo.comBioLife Solutions to Announce Preliminary 2022 Revenue and Introduce 2023 Revenue Guidance on January 9, 2023December 18, 2022 | finance.yahoo.comShould You Invest in BioLife Solutions (BLFS)?December 15, 2022 | msn.comBioLife Solutions's Return On Capital Employed InsightsDecember 10, 2022 | finance.yahoo.comInvestors push BioLife Solutions (NASDAQ:BLFS) 11% lower this week, company's increasing losses might be to blameNovember 21, 2022 | finance.yahoo.comBioLife Solutions Expands Intellectual Property EstateNovember 17, 2022 | finance.yahoo.comBioLife Solutions Named in BioSpace Best Places to Work in Biopharma 2023 ReportSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive BLFS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioLife Solutions and its competitors with MarketBeat's FREE daily newsletter. Email Address BLFS Company Calendar Last Earnings11/11/2021Today3/30/2023Next Earnings (Estimated)5/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Electromedical equipment Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BLFS CUSIPN/A CIK834365 Webwww.biolifesolutions.com Phone(425) 402-1400Fax425-402-1433Employees432Year FoundedN/APrice Target and Rating Average Stock Price Forecast$30.00 High Stock Price Forecast$34.00 Low Stock Price Forecast$27.00 Forecasted Upside/Downside+44.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($3.26) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-149,850,000.00 Net Margins-85.79% Pretax Margin-89.53% Return on Equity-6.79% Return on Assets-5.78% Debt Debt-to-Equity Ratio0.11 Current Ratio3.11 Quick Ratio2.76 Sales & Book Value Annual Sales$161.76 million Price / Sales5.49 Cash FlowN/A Price / Cash FlowN/A Book Value$8.52 per share Price / Book2.44Miscellaneous Outstanding Shares42,770,000Free Float41,355,000Market Cap$888.76 million OptionableNot Optionable Beta1.86 Key ExecutivesMichael P. RiceChairman & Chief Executive OfficerGeraint PhillipsSenior Vice President-Global OperationsTroy WichtermanChief Financial OfficerAby J. MathewChief Scientific Officer & Executive VPRoderick de GreefDirectorKey CompetitorsOutset MedicalNASDAQ:OMViewRayNASDAQ:VRAYZynexNASDAQ:ZYXIEdap TmsNASDAQ:EDAPAxoGenNASDAQ:AXGNView All CompetitorsInsiders & InstitutionsAby J MathewSold 10,000 sharesTotal: $214,400.00 ($21.44/share)Troy WichtermanSold 310 sharesTotal: $6,770.40 ($21.84/share)Troy WichtermanSold 10,000 sharesTotal: $206,400.00 ($20.64/share)Michael RiceSold 549 sharesTotal: $12,599.55 ($22.95/share)Aby J MathewSold 415 sharesTotal: $9,524.25 ($22.95/share)View All Insider TransactionsView All Institutional Transactions BLFS Stock - Frequently Asked Questions Should I buy or sell BioLife Solutions stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioLife Solutions in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BLFS shares. View BLFS analyst ratings or view top-rated stocks. What is BioLife Solutions' stock price forecast for 2023? 2 brokerages have issued 1 year price targets for BioLife Solutions' shares. Their BLFS share price forecasts range from $27.00 to $34.00. On average, they anticipate the company's share price to reach $30.00 in the next twelve months. This suggests a possible upside of 44.4% from the stock's current price. View analysts price targets for BLFS or view top-rated stocks among Wall Street analysts. How have BLFS shares performed in 2023? BioLife Solutions' stock was trading at $18.20 at the start of the year. Since then, BLFS shares have increased by 14.2% and is now trading at $20.78. View the best growth stocks for 2023 here. Are investors shorting BioLife Solutions? BioLife Solutions saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 2,120,000 shares, an increase of 10.4% from the February 28th total of 1,920,000 shares. Based on an average daily volume of 318,500 shares, the short-interest ratio is currently 6.7 days. Approximately 5.4% of the shares of the company are sold short. View BioLife Solutions' Short Interest. When is BioLife Solutions' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 8th 2023. View our BLFS earnings forecast. How were BioLife Solutions' earnings last quarter? BioLife Solutions, Inc. (NASDAQ:BLFS) posted its quarterly earnings data on Thursday, November, 11th. The medical equipment provider reported ($0.19) earnings per share for the quarter, missing the consensus estimate of $0.02 by $0.21. The medical equipment provider earned $33.80 million during the quarter, compared to analysts' expectations of $31.65 million. BioLife Solutions had a negative net margin of 85.79% and a negative trailing twelve-month return on equity of 6.79%. During the same quarter in the prior year, the firm earned ($0.02) earnings per share. What ETFs hold BioLife Solutions' stock? ETFs with the largest weight of BioLife Solutions (NASDAQ:BLFS) stock in their portfolio include Invesco S&P SmallCap Health Care ETF (PSCH), Principal Healthcare Innovators ETF (BTEC), First Trust Multi-Manager Small Cap Opportunities ETF (MMSC) and Invesco S&P SmallCap 600 Equal Weight ETF (EWSC).iShares Micro-Cap ETF (IWC), What guidance has BioLife Solutions issued on next quarter's earnings? BioLife Solutions updated its FY 2023 earnings guidance on Thursday, March, 16th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $188.00 million-$202.00 million, compared to the consensus revenue estimate of $195.65 million. What is Mike Rice's approval rating as BioLife Solutions' CEO? 14 employees have rated BioLife Solutions Chief Executive Officer Mike Rice on Glassdoor.com. Mike Rice has an approval rating of 100% among the company's employees. This puts Mike Rice in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 89.0% of employees surveyed would recommend working at BioLife Solutions to a friend. What other stocks do shareholders of BioLife Solutions own? Based on aggregate information from My MarketBeat watchlists, some companies that other BioLife Solutions investors own include Micron Technology (MU), AbbVie (ABBV), Cara Therapeutics (CARA), Gilead Sciences (GILD), Pfizer (PFE), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), Twilio (TWLO) and Verastem (VSTM). What is BioLife Solutions' stock symbol? BioLife Solutions trades on the NASDAQ under the ticker symbol "BLFS." Who are BioLife Solutions' major shareholders? BioLife Solutions' stock is owned by many different institutional and retail investors. Top institutional investors include Fred Alger Management LLC (4.62%), Geneva Capital Management LLC (3.55%), Palisade Capital Management LP (2.41%), Jennison Associates LLC (2.32%), Granahan Investment Management LLC (1.98%) and Millennium Management LLC (1.57%). Insiders that own company stock include Aby J Mathew, Aby J Mathew, Amy Duross, Andrew G Hinson, Andrew G Hinson, Casdin Partners Master Fund, L, Greef Roderick De, James Mathers, Joseph C Schick, Karen A Foster, Karen A Foster, Marcus Schulz, Michael Rice, Of The University Of C Regents, Raymond W Cohen, Sarah Aebersold, Thomas Girschweiler, Todd Berard, Troy Wichterman and Walter Villiger. View institutional ownership trends. How do I buy shares of BioLife Solutions? Shares of BLFS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is BioLife Solutions' stock price today? One share of BLFS stock can currently be purchased for approximately $20.78. How much money does BioLife Solutions make? BioLife Solutions (NASDAQ:BLFS) has a market capitalization of $888.76 million and generates $161.76 million in revenue each year. The medical equipment provider earns $-149,850,000.00 in net income (profit) each year or ($3.26) on an earnings per share basis. How many employees does BioLife Solutions have? The company employs 432 workers across the globe. How can I contact BioLife Solutions? BioLife Solutions' mailing address is 3303 MONTE VILLA PARKWAY SUITE 310, BOTHELL WA, 98021. The official website for the company is www.biolifesolutions.com. The medical equipment provider can be reached via phone at (425) 402-1400, via email at rdegreef@biolifesolutions.com, or via fax at 425-402-1433. This page (NASDAQ:BLFS) was last updated on 3/31/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.